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The CLSI epidemiological cutoff values (ECVs) of antifungal agents are available for various Candida spp., Aspergillus spp., and
theMucorales. However, those categorical endpoints have not been established for Fusarium spp., mostly due to the difficulties
associated with collecting sufficient CLSI MICs for clinical isolates identified according to the currently recommendedmolecular
DNA-PCR-based identification methodologies. CLSI MIC distributions were established for 53 Fusarium dimerum species com-
plex (SC), 10 F. fujikuroi, 82 F. proliferatum, 20 F. incarnatum-F. equiseti SC, 226 F. oxysporum SC, 608 F. solani SC, and 151 F.
verticillioides isolates originating in 17 laboratories (in Argentina, Australia, Brazil, Canada, Europe, Mexico, and the United
States). According to the CLSI guidelines for ECV setting, ECVs encompassing>97.5% of pooled statistically modeledMIC dis-
tributions were as follows: for amphotericin B, 4 g/ml (F. verticillioides) and 8 g/ml (F. oxysporum SC and F. solani SC); for
posaconazole, 2 g/ml (F. verticillioides), 8 g/ml (F. oxysporum SC), and 32 g/ml (F. solani SC); for voriconazole, 4 g/ml (F.
verticillioides), 16 g/ml (F. oxysporum SC), and 32 g/ml (F. solani SC); and for itraconazole, 32 g/ml (F. oxysporum SC and
F. solani SC). Insufficient data precluded ECV definition for the other species. Although these ECVs could aid in detecting non-
wild-type isolates with reduced susceptibility to the agents evaluated, the relationship betweenmolecular mechanisms of resis-
tance (gene mutations) andMICs still needs to be investigated for Fusarium spp.
While the genus Fusarium and its teleomorphic (sexual) formsencompass a variety of species, only some have been associ-
atedwith human disease. Identification of Fusarium isolates to the
accepted phylogenetic species complex (SC) or species level is es-
sential (1–4) but challenging, since important taxonomic changes
have been made, and the taxonomy is still in a state of flux for
some genera. Following the results of DNA-sequencing studies,
well-known prevalent fungal genera were divided into several new
genera. By 2013, the consensus was to continue using certain well-
known generic names and to have a single name for each fungal
species, including those in the genus Fusarium (5). In addition, the
names of the well-known Fusarium anamorphs, as they have been
used in the present paper, ought to be used instead of those of the
known teleomorphs (e.g., Haemonectria and Gibberella) (1–3).
However, the perception is that new generic changes may be sug-
gested, such as the establishment of the genus Bisifusarium to
include the more commonly known members of the Fusarium
dimerum SC and the nameNeocosmospora solani to replace Fusar-
ium solani (6). The most frequent causes of fungal infections are
members of three complexes, the F. solani species complex (SC),
the F. oxysporum SC, and the Fusarium (Gibberella) fujikuroi SC
(which includes, among others, F. verticillioides and F. prolifera-
tum), and the next most frequent causes belong to the F. dimerum
SC and F. incarnatum-F. equiseti SC; their distribution could be
region dependent (4, 7–10). Common clinical presentations are
onychomycosis, keratitis, allergic disease (sinusitis and broncho-
pulmonary disease) for nonimmunocompromised patients and
disseminated disease, as well as other severe invasive infections, in
immunocompromised hosts (e.g., patients with prolonged neu-
tropenia and T-cell immunodeficiency) (1, 4, 7–13). Amphoteri-
cin B lipid formulations, voriconazole, posaconazole, and, to a
lesser extent, itraconazole have been recommended or used for the
treatment and prophylaxis of Fusarium infections, in addition to
surgical debridement and reversal of immunosuppression (14–
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19). The survival rate is low, with some reports suggesting 30% or
less, for fusariosis, especially among patients with persistent neu-
tropenia (16–22). Successful therapeutic treatment of invasive
disease is usually associated with neutrophil recovery, a major
factor inmaking the setting of clinical breakpoints so challenging.
The new formulations of itraconazole and posaconazole have im-
proved bioavailability and reduced variability in exposure among
subjects (23, 24). However, the efficacy of these formulations in
the treatment of fusariosis has not been established.
A reproducible procedure for testing the antifungal suscepti-
bilities of Fusarium spp. is described by the Clinical and Labora-
tory Standards Institute (CLSI) Subcommittee on Antifungal Sus-
ceptibility Tests in document M38-A2 (25). However, neither
species-specific clinical breakpoints (BPs) nor epidemiological
cutoff values (ECVs) have been established for this fungal group.
The main reason, as for other, less-prevalent fungal species, is the
lack of both clinical trials and knowledge regarding molecular
resistancemechanisms for Fusarium spp. As a consequence, infor-
mation on the relationships between resistance mechanisms, low
and high MICs, and clinical response to therapy is not available.
However, it is still possible to define ECVs. These are calculated on
the basis of MIC distributions (100 MIC results per species and
antifungal agent) from multiple (3) independent laboratories
(26, 27; CLSI documents on ECVs under development). ECVs can
identify non-wild-type (non-WT [often harboring molecular
mechanisms of resistance]) isolates or isolates that are less suscep-
tible to the antifungal agent being evaluated. Although amphoter-
icin B and triazole MIC data have been reported for a variety of
Fusarium spp.,most available datawere obtained for isolates iden-
tified only to the genus level or by nonmolecular methods, or the
number of isolates evaluated was small (2, 4, 28–31). Therefore,
there was a need to pool data from multiple laboratories in order
to define ECVs for Fusarium spp.
The purposes of the present study were (i) to define the WT
susceptibility endpoint MIC distributions of the three most prev-
alent species/species complexes (the F. oxysporum SC, the F. solani
SC, and F. verticillioides) using aggregated CLSI M38-A2 broth
microdilution MIC data originating from 16 of the 17 participat-
ing laboratories and (ii) to propose ECVs for amphotericin B,
voriconazole, posaconazole, and itraconazole based on combina-
tions of antifungal agents and species or complexes for which
113 isolates originating from7 independent laboratories were
used. Pooled distributions of MICs of amphotericin B, voricona-
zole, posaconazole, and itraconazole for 10 to 82 isolates belong-
ing to less-prevalent species/complexes (e.g., F. dimerum SC, F.
fujikuroi, F. incarnatum-F. equiseti SC, F. proliferatum) were also
collated. We aggregated a total of 10 to 608 MICs (species and
antifungal agent dependent) obtained in the 17 participating lab-
oratories (in Argentina, Australia, Brazil, Canada, Europe, Mex-
ico, and the United States).
MATERIALS AND METHODS
Isolates. Each isolate was recovered from unique clinical specimens from
patients most of whom had eye, skin (sometimes both a cutaneous infec-
tion and infection of a nail or other organ), sinus, or pulmonary infections
or invasive disease (blood, lymph nodes). Antifungal susceptibility testing
was performed according to the CLSI brothmicrodilutionmethod (M38-
A2) at the following medical centers: VCU Medical Center, Richmond,
VA; Hospital São Paulo, Escola Paulista de Medicina—UNIFESP, São
Paulo, Brazil; Instituto Nacional de Enfermedades Infecciosas “Dr. C. G.
Malbrán,” Buenos Aires, Argentina; Institut National de Santé Publique
du Québec, Laboratoire de Santé Publique du Québec, Sainte-Anne-de-
Bellevue, Quebec, Canada; Provincial Laboratory, Alberta Health Ser-
vices, Edmonton, Canada; University Hospitals Case Medical Center and
Case Western Reserve University, Cleveland, OH; Universidad Au-
tónoma de Nuevo León, Monterrey, Nuevo León, Mexico; Facultat de
Medicina, IISPV, URV, Reus, Spain; National Mycology Reference Cen-
tre, SA Pathology, Adelaide, Australia; CanisiusWilhelminaHospital, Ni-
jmegen, The Netherlands; The Instituto Adolfo Lutz Reference Center,
São Paulo, Brazil; Hospital GeneralUniversitarioGregorioMarañón,Ma-
drid, Spain; JMI Laboratories, North Liberty, IA; Mycology Department,
The Instituto Adolfo Lutz Reference Center, São Paulo, Brazil; Grupo
Fleury, São Paulo, Brazil; Department of Biomedical Sciences for Health,
Università degli Studi di Milano, Milan, Italy; and the University of Texas
Health Science Center, San Antonio, TX.
The isolates were identified in each laboratory using conventional
methods (both macroscopic and microscopic characteristics on potato
dextrose agar) (1, 32) andwere confirmed byDNA-PCR-basedmolecular
assays (e.g., sequencing and amplification of -tubulin [BenA], transla-
tion elongation factor 1 [TEF], or the largest and/or second largest sub-
unit of RNA polymerase [RPB1 and/or RPB2, respectively], as well as
analysis of the internal transcribed spacer 1 [ITS1] and ITS2 regions) (1, 4,
10, 33, 34). The CLSI MICs of each of the four antifungal agents were
aggregated for 53 F. dimerum SC (including 1 F. delphinoides isolate), 10 F.
fujikuroi, 82 F. proliferatum, 20 F. incarnatum-F. equiseti SC, 226 F. oxys-
porum SC, 608 F. solani SC (including 11 F. falciforme isolates), and 151 F.
verticillioides isolates originating from 3 to 16 of the 17 independent lab-
oratories (see Table 1). Additionally, insufficient MIC data (10 isolates
from 2 to 3 laboratories) were provided for other members of the F.
fujikuroi SC, identified as F. sacchari, F. subglutinans, and F. thapsinum
(data not shown). Since molecular resistance mechanisms have not been
elucidated for Fusarium spp. and any antifungal agent, none of the isolates
were evaluated for gene mutations.
MIC data for at least one of the three quality control (QC) isolates
Candida parapsilosisATCC22019,C. kruseiATCC6258, andPaecilomyces
variotii ATCC MYA-3630 and/or for the reference isolate Aspergillus fla-
vus ATCC 204304 were reported by the participating laboratories (25).
Antifungal susceptibility testing. The MICs of amphotericin B and
the three triazoles (defined as the lowest drug concentrations that pro-
duced complete growth inhibition [100%] at 48 h [25]) for each available
isolate in the total set (see Tables 1 and 2) were determined in each center
by the CLSI broth microdilution method (with standard RPMI 1640
broth [0.2% dextrose] and final inoculum concentrations ranging from
0.4  104 to 5  104 CFU/ml). MICs for the Candida QC strains were
determined after 48 h by using the 50% (triazoles) and 100% (amphoter-
icin B) growth inhibition criteria (25). These MICs were within the rec-
ommended MIC limits with the following exceptions: discrepant MICs
for both theC. krusei andC. parapsilosisQC isolates and the triazoles were
observed, but the agreement (97.7 to 99.7%) was similar to or higher than
those listed in the M38-A2 document (25); the modes were within 1 dilu-
tion.
Definitions. As defined in the introduction, theWT is the population
of strains in a species-drug combination with no detectable acquired re-
sistance mechanisms. The ECV (orWT cutoff value [COWT]) is the high-
est MIC that would categorize an isolate as WT (without known mecha-
nisms of resistance) or, alternatively, the critical drug concentration value
that may identify those strains that have decreased susceptibility to the
agent being evaluated (non-WT isolates) or are potentially resistant (26,
27, 35).
Data analysis. The data were analyzed as reported previously in vari-
ous studies, by following theCLSI guidelines set forth for this purpose (26,
27, 35; CLSI documents on ECVs under development). Briefly, after the
MIC distributions for each combination of an antifungal agent and a
species or species complex from each laboratory were listed in an Excel
spreadsheet, they were reviewed for skewed/abnormal distributions
(e.g., the mode at the lowest concentration tested and/or bimodal [two
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modes in the same distribution]), which were not included in the
statistical analysis. According to CLSI recommendations (CLSI docu-
ments on ECVs under development) and following the examination of
global WT modal MIC variability, distributions for each antifungal
agent and species or species complex were pooled with the qualifying
data (abnormal distributions not included). ECVs were calculated for
each pooled distribution by the previously reported iterative statistical
technique that captured at least 95%, 97.5%, and 99% of the modeled
WT population (not the observed MICs) (35). In addition, we evalu-
ated the inherent variability (within approximately 1 doubling dilu-
tion) of susceptibility testing and the presence of outlier laboratories
in each pooled distribution.
RESULTS AND DISCUSSION
Susceptibility testing should aid in predicting patient response to
therapy, which is the specific role of the BP (36, 37). The CLSI has
established species-specific BPs only for testing the susceptibilities
of some Candida spp. to echinocandins, fluconazole, and vori-
conazole (38). The reason for this dearth of BPs is that their estab-
lishment requires particular steps: (i) WT MIC distributions and
ECVs for each species and agent being evaluated, (ii) the pharma-
cokinetic and pharmacodynamic (PK/PD) parameters of the
agent, (iii) knowledge of the relationship between mechanisms of
resistance and MICs, and, most importantly, (iv) the correlation
ofMICs with clinical response to treatment with the specific agent
in clinical trials (35–37). Data for these steps are not available for
Fusarium spp. However, we have gathered MIC distributions for
the F. oxysporum SC, the F. solani SC, and F. verticillioides (the
three species or complexes most commonly associated with hu-
man disease) with three triazoles and amphotericin B. Although
ECVs were not proposed for the other species evaluated due to
insufficient data, their pooledMICdistributions are listed inTable
1; the CLSI criteria require a minimum of 100 MICs/species
(MICs for 100 species-agent combinations) from at least three
laboratories and ECVs calculated by the iterative statistical
method (CLSI documents on ECVs under development). It is ex-
pected that the proposed ECVs would separate the two popula-
tions (WT and non-WT) that are present in the MIC distribution
of a species-agent combination. Although they would not distin-
guish between susceptible (treatable) and resistant (nontreatable)
isolates as BPs do, our proposed ECVs can help to identify those
isolates that are more likely to harbor acquired molecular muta-
TABLE 1 Pooled MIC distributions of amphotericin B and three triazoles for species of Fusarium from 3 to 16 laboratories as determined by the
CLSI broth microdilution methoda
Agent Species or SCb
No. of
labs
No. of
isolates tested
No. of isolatesc with a MIC (g/ml) of:
0.25 0.5 1 2 4 8 16 16
Amphotericin B F. dimerum SC 8 50 3 7 16 13 5 5 1
F. fujikuroi 3 10 1 6 3
F. proliferatum 10 82 1 5 16 31 22 5 1 1
F. verticillioides 9 151 1 27 84 28 6 5
F. incarnatum-F. equiseti SCd 6 20 3 3 5 6 3
F. oxysporum SC 14 226 1 10 37 107 61 8 2
F. solani SC 15 608 8 46 120 265 125 29 15
Itraconazole F. dimerum SC 7 45 3 1 15 25 1
F. fujikuroi 3 10 1 9
F. proliferatum 10 60 1 4 14 21 20
F. verticillioides 7 96 2 4 5 27 41 17
F. incarnatum-F. equiseti SC 6 20 1 1 2 8 6 2
F. oxysporum SC 9 148 2 2 4 29 87 24
F. solani SC 11 338 2 1 7 5 90 220 13
Posaconazole F. dimerum SC 7 48 1 2 3 5 25 11 1
F. fujikuroi 3 10 2 3 4 1
F. proliferatum 9 49 7 16 6 8 5 7
F. verticillioides 7 113 15 43 33 9 3 10
F. incarnatum-F. equiseti SC 6 19 3 2 5 6 2 1
F. oxysporum SC 10 148 1 20 53 37 13 22 2
F. solani SC 8 357 8 15 42 163 113 16
Voriconazole F. dimerum SC 7 53 3 9 15 24 2
F. fujikuroi 3 10 2 5 1 2
F. proliferatum 10 74 3 10 29 24 6 2
F. verticillioides 8 143 1 25 70 35 2 2 8
F. incarnatum-F. equiseti SC 6 20 1 2 5 8 3 1
F. oxysporum SC 13 200 5 10 36 94 47 5 3
F. solani SC 16 555 3 9 51 123 243 119 7
a MICs were determined by CLSI method M38-A2 (25).
b As identified by molecular methods (1, 4, 10, 33, 34). SC, species complex. F. fujikuroi, F. proliferatum, and F. verticillioides are members of the Fusarium (Gibberella) fujikuroi
species complex.
c The highest number in each row (showing the most frequently obtained MIC, or mode) is in boldface.
d A synonym for the Fusarium incarnatum-F. equiseti species complex is Fusarium semitectum.
ECVs for Fusarium spp. and Antifungal Agents
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tions conferring microbial resistance (non-WT isolates). This is
important in the absence of BPs for Fusarium spp.
Table 1 depicts the pooled MIC distributions for the four
agents and the Fusarium complexes/species evaluated. In general,
the MIC distributions were typical for each antifungal agent and
species, where 2 to 5 2-fold concentrations surround the modal
MIC. The exceptions were itraconazole and some voriconazole
distributions, which were skewed to the right. In addition, the
distributions from the different laboratories were comparable,
since their modal MICs for each combination of a species or spe-
cies complex with an agent were within 1 2-fold dilution of one
another, with three exceptions. The amphotericin B mode for F.
oxysporum SC was 1 dilution higher in one of the contributing
laboratories (4 g/ml versus 1 to 2 g/ml in the other laborato-
ries), while the posaconazole and voriconazole modes were 1 di-
lution lower for F. oxysporum SC and F. verticillioides (1 g/ml
versus 2 to 4 g/ml in the other laboratories) (data not shown in
Tables 1 and 2). Most amphotericin B modes were 2 g/ml; the
exceptions were the lower modes for F. dimerum SC and F. fuji-
kuroi and the higher mode for F. incarnatum-F. equiseti SC (Table
1). Among the triazoles, the highest values were observed when
itraconazole was tested (modes, 8 to 16 g/ml). Posaconazole
and voriconazole modes ranged from 0.5 to 8 g/ml and 2 to 8
g/ml, respectively, with the lowestmodes for F. verticillioides and
the highest for both the F. solani SC and the F. dimerum SC. The
MIC data (agent dependent) for 2 to 11 isolates of F. falciforme
were similar to those of their F. solani SC with one exception: the
eight posaconazole MICs for this species were 16 g/ml. The
same applied to the 4 to 8 isolates of the other three members of
the F. fujikuroi SC (F. sacchari, F. subglutinans, and F. thapsinum),
for which all itraconazole MICs were16g/ml (data not shown
in Table 1). Although some of the distributions for the less prev-
alent species are small, these results underline the need for iden-
tification to the species or complex level in addition to antifungal
susceptibility testing.
While the in vitro activities of the four antifungal agents eval-
uated are similar to those reported previously for Fusarium iso-
lates (both CLSI and EUCAST [European Committee on Antimi-
crobial Susceptibility Testing] MICs) (2, 4, 28–31), overall, our
MIC ranges are wider (Tables 1 and 2). In addition to our aggre-
gated itraconazole data, this was evident with amphotericin B
MICs for both the F. proliferatum and F. oxysporum SCs and with
voriconazole MICs for the F. solani SC. However, the number of
isolates for each pooled distribution was higher than those tested
in prior studies (2, 4, 28–31) (15 to 22 isolates for more-prevalent
species) and perhaps better represented the range of susceptibili-
ties to these agents. Nevertheless, the most frequent MICs (when
provided) were similar to those in the present study. To our
knowledge, pooled MIC data are not available for the less-preva-
lent species. Based on these data and the widespread geographical
regions from which our pooled MIC data originated, we assume
that our data are valid.
As mentioned above, the CLSI has set forth criteria for the
calculation of species-specific ECVs based on unmodified CLSI
methodologies for MIC determination (100 isolates originating
in at least three independent laboratories per species-agent com-
bination) and for the calculation of the ECV percentage (97.5%
values) by the iterative statistical technique (CLSI documents on
ECVs under development). Since 97.5% values risk classifying
some isolates with acquired resistance mechanisms as WT, we
have also provided the95% and99% ECVs. Either the values
were the same or the97.5 and99% ECVs were separated by 1
dilution. Table 2 depicts the ECVs for the aggregated MIC distri-
butions that met the CLSI criteria: amphotericin B, itraconazole,
posaconazole, and voriconazole versus the F. oxysporum SC, the F.
solani SC, and F. verticillioides. Insufficient data precluded the cal-
culation of ECVs for the combination of itraconazole and F. ver-
ticillioides or any other species. The ECVs of amphotericin B were
4 g/ml (F. verticillioides) and 8 g/ml (F. oxysporum SC and F.
solani SC); these values are actually above what is anecdotally con-
sidered the notional “breakpoint” for resistance among some
Aspergillus spp. (2 g/ml). Similarly high ECVs were observed
among Aspergillus spp., Mucor circinelloides, and Rhizopus arrhi-
zus (26, 39). As expected, the highest ECVs were those of the three
triazoles for the F. solani SC (32 g/ml). Lower posaconazole and
voriconazole ECVs were calculated for F. verticillioides (2 and 4
g/ml, respectively) and the F. oxysporum SC (8 and 16 g/ml,
respectively). These triazole ECVs are mostly higher than the ex-
pected maximal, variable, and dose-dependent trough levels of
each of the agents (23, 24, 40) and highlight the intrinsically resis-
tant nature of Fusarium spp. The same applies to amphotericin B
values.
Although case series of Fusarium infections have been reported
throughout the years (4, 7, 9, 16, 20–22), only in a recent report
was an indication of a potential correlation between MICs for
Fusarium spp. and response to treatment found (22), where CLSI
MICs for seven Fusarium isolates identified by molecular meth-
ods, antifungal therapy (voriconazole or both voriconazole and
amphotericin B), and clinical response were documented for pa-
tients with invasive fusariosis. Favorable clinical responses were
reported for twoof the sevenpatients infectedwithF. verticillioides
(voriconazole MICs, 2 and 4 g/ml, respectively); according to
our voriconazole ECV for this species, both infecting strains
TABLE 2 Epidemiologic cutoff values of amphotericin B, itraconazole,
posaconazole, and voriconazole for two clinically relevant Fusarium
species complexes and F. verticillioides as determined by the CLSI broth
microdilution methoda
Species or
species complex
Antifungal
agentb
MIC (g/ml)
Calculated statistical ECV
(g/ml)c
Range Moded 95% 97.5% 99%
F. verticillioides AMB 0.5–16 2 4 4 4
ITR 1–16 16 ND ND ND
POS 0.25–16 0.5 2 2 2
VOR 0.5–16 2 4 4 8
F. oxysporum SC AMB 0.25–16 2 4 8 8
ITR 1–16 16 32 32 32
POS 0.5–16 2 8 8 8
VOR 0.5–16 4 8 16 16
F. solani SC AMB 0.25–16 2 4 8 8
ITR 0.5–16 16 16 32 32
POS 1–16 8 32 32 32
VOR 0.5–16 8 16 32 32
a ECVs were defined for pooled distributions for100 isolates from3 laboratories
using the methodology of CLSI document M38-A2 (25, 35).
b AMB, amphotericin B; ITR, itraconazole; POS, posaconazole; VOR, voriconazole.
c Calculated ECVs comprising95%,97.5%, and99% of the statistically modeled
population. ND, not determined (due to insufficient data).
d MIC most frequently obtained for each distribution.
Espinel-Ingroff et al.
1082 aac.asm.org February 2016 Volume 60 Number 2Antimicrobial Agents and Chemotherapy
 o
n
 February 2, 2016 by UNIV DEG
LI STUDI DI M
ILANO
http://aac.asm
.org/
D
ow
nloaded from
 
would be considered WT isolates (Table 2). Of the four patients
infected with F. solani, the correlation was evident for only one (a
favorable clinical response and a voriconazole MIC of 4g/ml, or
another WT strain). The remaining three patients failed therapy;
two of them were treated with both voriconazole and amphoteri-
cin B (amphotericin B MICs, 4 g/ml; voriconazole MICs, 8
g/ml or16g/ml). These amphotericin BMICs could be con-
sidered WT, and both voriconazole MICs would more likely be
considered non-WT, although the final MIC endpoint was not
given (voriconazole ECV for the F. solani SC, 32g/ml).However,
it is important to keep in mind that categorization of an isolate as
WT does not indicate that the isolate is susceptible (treatable),
given that ECVs do not predict clinical response to therapy. Sim-
ilarly, other factors preclude correlations of in vitro and clinical
responses to therapy in other studies, where cultures, species, and
especially MICs are not reported and the response was influenced
by the site of infection, the underlying disease, and/or the reversal
of immunosuppression. In addition, the molecular mechanisms
of resistance have not been evaluated for any Fusarium isolate
causing human disease, as they have been for Candida and Asper-
gillus. As found with theMucorales, the molecular biology of Fus-
arium sp. resistance needs to be investigated.
In conclusion, species-specific amphotericin B ECVs (com-
prising 97.5% of the modeled populations) of 4 g/ml (F. ver-
ticillioides) and 8 g/ml (F. oxysporum SC and F. solani SC), po-
saconazole ECVs of 2 g/ml (F. verticillioides), 8 g/ml (F.
oxysporum SC), and 32g/ml (F. solani SC), voriconazole ECVs of
4 g/ml (F. verticillioides), 16 g/ml (F. oxysporum SC), and 32
g/ml (F. solani SC), and itraconazole ECVs of 32 g/ml (F. ox-
ysporum SC and F. solani SC) have been proposed based on CLSI
data from multiple laboratories. ECVs were mostly 1 dilution
lower when 95% of the modeled populations was used, which
could be more clinically relevant. Like the ECVs for Candida spp.
and Aspergillus spp., the proposed ECVs for the more-prevalent
Fusarium spp. may aid in the detection of strains with acquired
mechanisms of resistance (non-WT) to the agents evaluated.
However, ECVs are not BPs and cannot predict clinical response
to therapy, and categorization of an isolate as WT does not mean
that it is necessarily treatable or susceptible. Also, as for the Mu-
corales, knowledge regardingmolecularmechanisms of resistance
and their relationship with MICs is needed.
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